Piramal Pharma, a leading global pharmaceutical company, has achieved a significant improvement in its score on the Global Corporate Sustainability Assessment (CSA) conducted by S&P Global. The CSA is a widely recognized benchmark for assessing a company’s sustainability performance, evaluating factors such as environmental, social, and governance (ESG) practices.
In the latest assessment, Piramal Pharma’s score has increased by 13 points, reaching a total of 73 out of 100. This improvement reflects the company’s ongoing efforts to integrate sustainability into its business strategy and operations. The CSA assessment is based on a comprehensive evaluation of a company’s sustainability practices, including climate change, human rights, labor practices, and corporate governance.
The significant improvement in Piramal Pharma’s score can be attributed to its focused efforts on reducing its environmental footprint, enhancing its governance practices, and promoting social responsibility. Some of the key initiatives that contributed to this improvement include:
- Renewable energy: Piramal Pharma has increased its use of renewable energy sources, such as solar and wind power, to reduce its dependence on fossil fuels and lower its carbon emissions.
- Water conservation: The company has implemented water-saving measures and efficient wastewater management systems to minimize its water footprint.
- Waste reduction: Piramal Pharma has implemented a waste reduction program, which includes recycling and composting, to minimize waste disposal and reduce its environmental impact.
- Corporate governance: The company has strengthened its corporate governance practices, including board composition, executive compensation, and auditing practices.
- Social responsibility: Piramal Pharma has continued to invest in social responsibility initiatives, such as education, healthcare, and community development programs, to promote positive social impact.
The improved score on the Global Corporate Sustainability Assessment reflects Piramal Pharma’s commitment to sustainability and its efforts to create long-term value for its stakeholders. The company’s focus on sustainability is aligned with its mission to improve the quality of life for patients and communities worldwide. By integrating sustainability into its business strategy, Piramal Pharma aims to minimize its environmental footprint, promote social responsibility, and ensure long-term success.
Overall, Piramal Pharma’s achievement on the Global Corporate Sustainability Assessment demonstrates its dedication to sustainability and its commitment to creating a positive impact on the environment, society, and the economy. The company’s improved score serves as a testament to its efforts to balance business growth with social and environmental responsibility, making it a leader in the pharmaceutical industry.